What is the global market size of the Cholera Vaccines Market?

Global Cholera Vaccines Market size was valued at USD 86.27 million in 2021 and is poised to grow from USD 95.22 million in 2022 to USD 191.13 million by 2030, growing at a CAGR of 9.1% in the forecast period (2023-2030).

Who are the key vendors in the Global Cholera Vaccines Market?

The report provides a detailed analysis of the following key players in the global cholera vaccines market, including their competitive landscape, capacity, and most recent developments such as mergers, acquisitions, and investments, capacity expansions, and plant turnarounds. The presence of 'Sanofi S.A.', 'GlaxoSmithKline plc', 'PaxVax Inc. (now part of Emergent BioSolutions)', 'Bharat Biotech', 'Valneva SE', 'EuBiologics Co. Ltd.', 'Shantha Biotechnics Private Limited (part of Sanofi Pasteur)', 'Bio Farma (Indonesia Vaccine Institute)', 'Eubiologics Co. Ltd.', 'Merck & Co., Inc.', 'Cipla Limited', 'Astellas Pharma Inc.', 'Takeda Pharmaceutical Company Limited', 'Panacea Biotec Ltd.', 'Serum Institute of India Pvt. Ltd.', 'Beijing Minhai Biotechnology Co. Ltd.', 'Biken Corporation', 'OCV Consortium (The Bill and Melinda Gates Foundation, WHO, and others)', 'PaxVax Bermuda Ltd.', 'GSK Biologicals SA.'

Cholera Vaccines Market Size, Share, Growth Analysis, By End user(Hospitals, specialty clinics, research and academic laboratories and pharmaceutical and biotechnology companies and others), By Type(Dukoral, Shanchol, Vaxchora, Euvichol), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35I2103 | Region: Global | Published Date: July, 2024
Pages: 219 | Tables: 65 | Figures: 75

Cholera Vaccines Market News

In May 2023, the International Vaccine Institute (IVI) began clinical development of DuoChol, a new low-cost oral cholera vaccine (OCV) in capsule form. With funding support from the Wellcome Trust and the Swedish government, IVI is preparing to conduct a Phase I clinical trial of the vaccine in Sweden.
In February 2023, Bavarian Nordic completed the acquisition of Emergent BioSolutions’ travel vaccine portfolio for an upfront payment of $274million, with the potential for the total value to rise to $384million. The deal encompasses Vivotif and Vaxchora, both marketed vaccines for the prevention of typhoid fever and cholera respectively, and a Phase III vaccine candidate for the prevention of Chikungunya virus, which have now all been transferred to Bavarian Nordic.
In November 2022, South Africa's Biovac Institute signed a licensing and technology transfer deal with the International Vaccine Institute (IVI) to develop and make oral cholera vaccine for African and global markets.

Cholera Vaccines Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Cholera Vaccines Market was valued at USD 73.69 million in 2022, and is expected to rise from USD 79.07 million in 2023 to reach a value of USD 138.93 million by 2031, rising at a CAGR of 7.30 % during the forecast period 2024-2031.

The report provides a detailed analysis of the following key players in the global cholera vaccines market, including their competitive landscape, capacity, and most recent developments such as mergers, acquisitions, and investments, capacity expansions, and plant turnarounds. The presence of 'Sanofi S.A.', 'GlaxoSmithKline plc', 'PaxVax Inc. (now part of Emergent BioSolutions)', 'Bharat Biotech', 'Medtronics', 'EuBiologics Co. Ltd.', 'Shantha Biotechnics Private Limited (part of Sanofi Pasteur)', 'Bio Farma (Indonesia Vaccine Institute)', 'Eubiologics Co. Ltd.', 'Merck & Co., Inc.', 'Cipla Limited', 'Astellas Pharma Inc.', 'Takeda Pharmaceutical Company Limited', 'Panacea Biotec Ltd.', 'Serum Institute of India Pvt. Ltd.', 'Beijing Minhai Biotechnology Co. Ltd.', 'Biken Corporation', 'OCV Consortium (The Bill and Melinda Gates Foundation, WHO, and others)', 'PaxVax Bermuda Ltd.', 'GSK Biologicals SA.'

The development of creative methods to new cholera vaccines, increased awareness of cholera preventative care, and adoption of unhealthy lifestyle habits including poor sanitation and consumption of tainted food are the factors anticipated to propel the growth of the cholera vaccines market. Additionally, a greater focus on immunisation campaigns by the government has fueled the market expansion for cholera vaccines. The global cholera vaccines market, however, may be hindered by the FDA's stricter criteria and longer approval process for new drugs.

The global market is primarily driven by the increasing prevalence of cholera among the general population. This is due to poor sanitation and hygiene conditions in rural and geographically remote areas. Furthermore, rising public awareness of the availability of cholera vaccines has boosted product demand.

The market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa (MEA). According to regional analysis, Asia-Pacific has the largest market share. This is due to increased access to effective preventive measures, rise in public awareness of the disease, and the disease's high incidence rate. Europe is also expected to grow steadily during the forecast period, owing to the region's well-established healthcare infrastructure. North America, on the other hand, is expected to grow at a faster rate during the forecast period, owing to rising consumption of contaminated food, a lack of appropriate hygiene, and an increasing number of migrants. At the same time, increased R&D activities, rising public awareness of vaccination, and rising government initiatives to conduct immunisation programmes would all contribute to the growth of the cholera vaccine market in this region.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Cholera Vaccines Market Size, Share, Growth Analysis, By End user(Hospitals, specialty clinics, research and academic laboratories and pharmaceutical and biotechnology companies and others), By Type(Dukoral, Shanchol, Vaxchora, Euvichol), By Region - Industry Forecast 2024-2031

Cholera Vaccines Market News

Cholera Vaccines Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Cholera Vaccines Market?

Who are the key vendors in the Cholera Vaccines Market?

What is the key driver of Cholera Vaccines Market?

What is the key market trend for Cholera Vaccines Market?

Which region accounted for the largest share in Cholera Vaccines Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300